Table1

	Overall	Non-Massive Weight Gain	Massive Weight Gain*	Bivariate OR (95% CI)	Bivariate p-value	Multivariate OR (95% CI)	Multivariate p-value
	266	213	53				
Age (median, IQR)	36 (29 – 45)	37 (30 -44)	35 (28 – 46)	1.0 (0.7 – 1.3)	0.95		
Female (n,%)	25 (9%)	17 (8%)	8 (15%)	2.0 (0.8 – 5.0)	0.12	1.7 (0.6 – 4.8)	0.35
Black (n,%)	38 (14%)	31 (15%)	7 (13%)	0.9 (0.3 – 2.2)	0.70		
Hispanic (n,%)	114 (43%)	92 (43%)	22 (42%)	0.9 (0.5 – 1.8)	0.76		
White (n,%)	106 (40%)	84 (39%)	22 (42%)				
Baseline CD4 (cells/ul) (median, IQR)	288 (157 – 435)	319 (199 – 441)	88 (31 – 284)	0.6** (0.5 – 0.8)	<0.0001	0.8** (0.6 – 0.9)	0.01
Baseline HIV Viral Load (cps/ml) (median, IQR)	63369 (23952 – 154283)	52864 (19008 – 108764)	168000 (88128 – 494432)	3.9**(2.2 –6.7)	<0.0001	3.9**(2.2 – 6.7)	0.002
Weight at baseline (lbs) (median, IQR)	163 (142-182)	167 (147-185)	145 (132-161)				
% Weight Gain at 2 years (median, IQR)	4.0 (-1.1 – 11.6)	2.0 (-1.9 – 6.5)	20.6 (16.7 – 33.6)				
Baseline BMI (kg/m²) (median, IQR)	23.7 (21.4 – 27.0)	23.9 (22.0 – 27.6)	22.6 (20.7 – 25.0)	0.9 (0.8 – 1.0)	0.007	0.9 (0.9 – 1.0)	0.19
Regimen							
INSTI (n,%)	94 (35%)	78 (37%)	16 (30%)	0.4 (0.2 – 1.0)	0.26	0.7 (0.3 – 1.9)	0.97
NNRTI (n,%)	112 (42%)	94 (44%)	18 (34%)	0.4 (0.2 – 0.9)	0.14	0.6 (0.2 – 1.3)	0.23
PI (n,%)	60 (23%)	41 (19%)	19 (36%)	-	-		
NRTI							
ABC (n,%)	27 (10%)	21 (10%)	6 (11%)	1.2 (0.4 – 3.1)	0.80		
TAF (n,%)	43 (16%)	34 (16%)	9 (17%)	1.1 (0.5 – 2.5)	0.98		
TDF (n,%)	196 (74%)	158 (74%)	38 (72%)				

* Massive weight gain defined as the top 20% of weight gainers at two years measured by percent gain compared to baseline; **OR reported per 100 cells/ul CD4 count increase and 1 log viral load increase. IQR, interquartile range; lbs, pounds; BMI, body mass index; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor, PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; ABC, abacavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate, OR, odds ratio

Conclusion. In this real-world dataset, drug class or specific NRTI use was not associated with massive weight gain which was primarily dependent on baseline CD4 count and HIV viral load. There was a moderate correlation between early weight gain and massive weight gain at 2 years which can help with patient counseling and interventions aimed at slowing weight gain in this population.

Disclosures. **All Authors**: No reported disclosures

## 73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks

Laurie VanderVeen, PhD[1]; Nicolas Margot, MA[1]; Vidula Naik, MSc[1]; Silvia Chang, Masters[1]; Ross Martin, PhD[1]; Hadas Dvory-Sobol, PhD[1]; Martin Rhee, MD[1]; Christian Callebaut, PhD[1]; [1]Gilead Sciences, Foster City, California

Session: O-16. HIV Treatment

Background. Lenacapavir (LEN) is a first-in-class HIV-1 capsid (CA) inhibitor in clinical development for treatment and prevention of HIV-1 infection. CALIBRATE is an ongoing, phase 2 clinical study evaluating subcutaneous (SC) or oral LEN, in combination with other antiretrovirals, in treatment-naïve people with HIV-1. High rates of virologic success (HIV-1 RNA < 50 copies/mL) were achieved with LEN-based regimens by FDA Snapshot analysis at Week 28. Here, we present interim resistance analyses through Week 28.

Methods. Participants were randomized (2:2:2:1) to treatment groups (TG) (Figure): SC LEN + oral daily emtricitabine/tenofovir alafenamide (F/TAF); at Week 28, participants switch F/TAF to oral TAF (TG-A) or bictegravir (B, BIC) (TG-B); oral daily LEN + F/TAF (TG-C), or oral daily B/F/TAF (TG-D). Genotypic analyses (population sequencing) of HIV-1 reverse transcriptase and integrase, and genotypic (deep sequencing)/phenotypic analyses for CA were performed at screening; genotypic and phenotypic analyses were conducted at confirmed virologic failure.

Figure. CALIBRATE Study Design

Results. 182 participants were randomized and dosed in TG-A to D (n=52, 53, 52, 25). Most participants had subtype B HIV-1 (92.9%). Sequence analysis of baseline samples found 65% of amino acid residues were conserved with < 1% variation across CA overall, and 55% of residues were fully conserved. No mutations were detected at 6 positions in CA associated with reduced susceptibility to LEN in vitro; residues were fully conserved at 5 positions (L56, M66, Q67, K70, N74), and < 2% variation was observed at 1 position (T107). Three participants met the criteria for resistance analysis: 2 participants resuppressed to < 50 copies/mL while continuing treatment. One participant on SC LEN + F/TAF developed emergent resistance to LEN (Q67H+K70R) and emtricitabine (M184M/I), followed by resuppression after starting dolutegravir, zidovudine + lamivudine, tenofovir disoproxil fumarate.

Conclusion. Emergent resistance to LEN was uncommon in treatment-naïve participants receiving SC or oral LEN (0.6%, 1/157). These interim resistance findings support the ongoing evaluation of LEN for treatment and prevention of HIV.

74. Maternal Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: The Antiretroviral Pregnancy Registry (APR)

Vani Vannappagari, MBBS, MPH, PhD[1]; Jessica Albano, PhD, MPH[2]; Leigh Ragone, MS[1]; Taylor Cook, BS[2]; Angela Scheuerle, MD[3]; William R. Short, MD[4]; Claire Thorne, MSc, PhD[5]; Karen P. Beckerman, MD[6]; Nahida Chaktoura, MD, MsGH [7]; Lynne Mofenson, MD[8]; [1]ViiV Healthcare, Research Triangle Park, NC; [2]Syneos Health, Wilmington, North Carolina; [3]University of Texas Southwestern Medical Center, Dallas, Texas; [4]University of Pennsylvania, PA; [5]University College London Great Ormond Street Institute of Child Health, London, England, United Kingdom; [6]Staten Island University Medical Center, New Rochelle, New York; [7]NICHD, Bethesda, MD; [8]Elizabeth Glaser Pediatric AIDS Foundation, Silver Spring, Maryland

Session: O-16. HIV Treatment

Background. The APR is prospective exposure-registration cohort study, monitoring for early warning signals of major teratogenic effects of antiretrovirals (ARV) used during pregnancy. This analysis aimed to assess maternal demographics, pregnancy and neonatal outcomes including birth defects among infants with periconception and prenatal exposure to DTG using APR data.

Methods. Descriptive analysis with frequency tabulation of pregnancy and neonatal outcomes is reported. Periconception is defined as any exposure within two weeks prior to or through 28 days after conception.

Results. There were 1010 prospectively reported pregnancies with exposure to DTG through 31January2021, with 526 periconception exposures, 105 exposed later during 1st trimester, 260 during 2nd trimester and 119 during 3rd trimester. Maternal median age at conception was 30 years and 77.0% of pregnancies were reported from the United States. At the time of reporting, 46.6% had CD4 count ≥500 cells/μL, 31.8% had 200-499 cells/μL, 12.5% had < 200 cells/μL and 9.1% unknown.

The 1010 DTG exposed pregnancies resulted in 1036 outcomes: 956 (92.3%) live births (26 twin pairs), 12 (1.2%) stillbirths, 28 (2.7%) induced abortions, and 38 (3.7%) spontaneous abortions. Among live births, 39 (4.1%) reported birth defects. For 1st trimester exposures, overall defect prevalence was 3.3% (19/576, 95% CI:2.0-5.1) and for 2nd/3rd trimester exposures defect prevalence was 5.3% (20/380, 95% CI:3.2-8.0). One neural tube defect (NTD) case of anencephaly with periconception DTG exposure was reported.

Among the 873 singleton, live births without birth defects, 92 (10.5%) were preterm (< 37 weeks of gestation); 103 (11.8%) had low birth weight (lbw) < 2500 grams including 22 (2.5%) < 1500 (very lbw) grams.

Table 1. Birth Defect Outcomes of Pregnant Women Exposed to DTG Prospective Registry Cases with Follow-up Closed through 31 January 2021

	Total Outcomes N	Live Births	Defect* Cases	CNS Defect (1,2)	NTD Cases (1)	Encephalocele (2)
Any InSTI Exposure [3]	2435	2243	77	7	1	0
Periconception	1402	1244	38	4	1	0
Later First Trimester	206	195	5	1	0	0
Second/Third Trimester	821	800	34	2	0	0
Any Dolutegravir Exposure [3]	1036	956	39	5	1	0
Periconception	539	475	16	2	1	0
Later First Trimester	107	101	3	1	0	0
Second/Third Trimester	390	380	20	2	0	0

Note: ART = antiretroviral therapy; CNS = central nervous system; NTD = neural tube defect.
Note: Periconception is defined as any exposure 2 weeks prior to conception through 28 days gestational age; Later First Trimester is defined as any exposure in the first trimester that begins after 28 days gestational age.
[1] NTD cases are a subset of CNS defects and are counted in both columns.
[2] Encephalocele cases are a subset of CNS defects and are counted in both columns.
[3] Includes cases with missing trimester of exposure.
* Comparators for population expected rate of defects (2.72 - 4.17/ 100 live births from MACDP and TBDR respectively).
MACDP =Metropolitan Atlanta Congenital Defects Program; TBDR=Texas Birth Defects Registry

Table 2. Neonatal Outcomes (among Singleton, Live Births without Birth Defects) Prospective Registry Cases with Follow-up Closed through 31 January 2021

Neonatal Outcomes	Overall DTG Exposed	Barliest exposure to DTG - Periconception	Barliest exposure to DTG - Later 1st Trimester	Barliest exposure to DTG - 2nd/3rd Trimester
Total Outcomes, N	873	436	94	343
Gestational Age*				
>= 37 weeks	778 (89.1%)	387 (88.8%)	80 (85.1%)	311 (90.7%)
< 37 weeks (Preterm)	92 (10.5%)	48 (11.0%)	14 (14.9%)	30(8.7%)
Missing	3 (0.3%)	1 (0.2%)	0	2 (0.6%)
Birth Weight*				
>= 2500 grams	750 (85.9%)	368 (84.4%)	83 (88.3%)	299 (87.2%)
< 2500 grams (LBW)	103 (11.8%)	55 (12.6%)	11 (11.7%)	37 (10.8%)
< 1500 grams (very LBW)	22 (2.5%)	14 (3.2%)	3 (3.2%)	5 (1.5%)
Missing	20 (2.3%)	13 (3.0%)	0	7 (2.0%)

DTG = Dolutegravir; LBW = Low Birth Weight.
*Among singleton, live births without birth defects.
Note: Periconception is defined as any exposure 2 weeks prior to conception through 28 days gestational age; Later First Trimester is defined as any exposure in the first trimester that begins after 28 days gestational age; Second Trimester begins at 14 weeks gestational age and Third Trimester begins at 28 weeks gestational age.

Conclusion. APR data do not demonstrate an increased risk of overall birth defects with DTG use above the population expected rate of defects (2.72 to 4.17 per 100 live births from Metropolitan Atlanta Congenital Defects Program [MACDP] and Texas Birth Defects Registry [TBDR] respectively). The number of periconception exposure outcomes is not yet sufficient to evaluate potential association of DTG with NTD. The Registry continues to closely monitor birth defects, including NTDs in pregnancies exposed to DTG and other integrase inhibitors.

Shareholder) **Leigh Ragone, MS**, GlaxoSmithKline (Shareholder)**ViiV Healthcare** (Employee) **Taylor Cook, BS**, Syneos Health (Employee) **Angela Scheuerle, MD**, ViiV (Independent Contractor) **William R. Short, MD**, Gilead Sciences (Individual(s) Involved: Self): Consultant; ViiV (Individual(s) Involved: Self): Consultant **Claire Thorne, MSc, PhD**, MSD (Grant/Research Support)**ViiV Healthcare** (Grant/Research Support, Other Financial or Material Support, Contributor to Think Tank)

75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study

Charlotte-Paige M. Rolle, MD MPH[1]; Mezgebe Berhe, MD[2]; Tulika Singh, MD MS AAHIVS[3]; Roberto Ortiz, MD[4]; Anson K. Wurapa, MD[5]; Moti Ramgopal, MD FIDSA[6]; Dushyantha Jayaweera, MD, mrcog(uk), face[7]; Peter Leone, MD[8]; Jessica Matthews, BS[8]; Michael Cupo, Ph.D.[9]; Mark Underwood, PhD[8]; Kostas Angelis, PhD[10]; Brian Wynne, MD[8]; Deanna Merrill, PharmD, MBA, AAHIVP[8]; Christopher T. Nguyen, MD[8]; Jean A. van Wyk, MB,ChB[8]; Andrew Zolopa, MD[8]; [1]Orlando Immunology Center, Orlando, Florida; [2]North Texas Infectious Diseases Consultants, Dallas, TX; [3]University of California, Riverside, Palm Springs, CA; [4]Bliss Healthcare Services, Orlando, Florida; [5]Infectious Disease Specialists of Atlanta, Atlanta, GA; [6]Midway Specialty Care Centers, Fort Pierce, Florida; [7]University of Miami, Miami, Florida; [8]ViiV Healthcare, Chapel hill, North Carolina [9]GlaxoSmithKline, Collegeville, PA; [10]GSK, London, England, United Kingdom

Session: O-16. HIV Treatment

Background. The primary analysis of the STAT study demonstrated the feasibility, efficacy, and safety of using DTG/3TC as a first-line regimen in a test-and-treat setting through 24 weeks, with therapy adjustments for baseline resistance or hepatitis B virus (HBV) co-infection. Here we present secondary analyses through Week 48 of virologic outcomes in participants by baseline viral load (VL).

Methods. STAT is a single-arm study of treatment-naive adults with HIV-1 infection who initiated DTG/3TC ≤ 14 days after HIV-1 diagnosis without availability of screening/baseline laboratory results. If baseline testing indicated DTG or 3TC resistance, HBV co-infection, or creatinine clearance < 30 mL/min/1.73 m², then antiretroviral therapy (ART) was potentially adjusted and participants remained on study. Efficacy analyses included proportion of participants with HIV-1 RNA < 50 c/mL regardless of ART regimen at Week 48, among all participants (ITT-E missing = failure analysis) and among participants with available HIV-1 RNA data at Week 48 (observed analysis).

Results. Of 131 enrolled, DTG/3TC treatment was adjusted in 10 participants, and of those with available data (n=7), all (100%) achieved HIV-1 RNA < 50 c/mL at Week 48. At Week 48, 82% (107/131) of all participants (Figure 1) and 97% (107/110) of those with available data (Figure 2) achieved HIV-1 RNA < 50 c/mL. Of participants with baseline VL ≥ 500,000 c/mL, 89% (17/19) achieved HIV-1 RNA < 50 c/mL at Week 48; the remaining 2 withdrew from study. Of participants with baseline VL ≥ 1,000,000 c/mL, 90% (9/10) achieved HIV-1 RNA < 50 c/mL at Week 48 (Table); the remaining participant withdrew consent. Of the 17 participants with baseline VL ≥ 500,000 c/mL with available data through Week 48, 76% (13/17) achieved virologic suppression by Week 24. One participant with baseline VL ≥ 500,000 c/mL switched from DTG/3TC before the Week 48 assessment. Of the 9 participants with baseline VL ≥ 1,000,000 c/mL with available data through Week 48, most participants (8/9; 89%) were suppressed by Week 24.

Figure 1. Virologic outcomes at Week 48, overall and by baseline VL and CD4+ cell count: ITT-E missing = failure analysis.


Figure 2. Virologic outcomes at Week 48, overall and by baseline VL and CD4+ cell count: observed analysis.


Table. Viral Load by Study Visit Among Participants with Baseline HIV-1 RNA ≥1,000,000 c/mL

Participant	Baseline CD4+ cell count	Baseline	Week 1	Week 4	Week 8	Week 12	Week 24	Week 36	Week 48
A	410	68,706,840	518,812	9781	NA	90,912	NA*	—	—
B	128	13,987,640	123,843	1682	297	493	191/ 157 / 302	124	63 / 48
C	613	5,794,931	98,499	96	<40	<40	<40	<40	<40
D	534	5,034,556	33,293	304	<40	<40	NA	<40	<40
E	464	2,592,169	1046	115	<40†	<40	<40	<40	<40
F	387	2,319,328	19,210	122	<40	52	<40	<40	<40
G	532	2,252,702	6241	136	48	42	<40	NA	<40
H	671	1,981,995	8373	245	<40	<40	<40	<40	<40
I	56	1,291,792	2618	222	147	71	<40	<40	<40
J	94	1,013,606	8646	725	242	185	<40	<40	<40

Values after / denote viral load at retesting. Green denotes virologic suppression on DTG/3TC; light green denotes virologic suppression on modified ART (see footnote).
NA, not available.
*Participant confirmed many missed doses before Week 12 and withdrew consent due to incarceration. †Participant switched to DRV/COBI/FTC/TAF on Day 92 (Week 12) due to AE (rash); participant switched again to BIC/FTC/TAF on Day 113 (Week 12) due to a different rash.

Conclusion. These data provide evidence for the efficacy and feasibility of using DTG/3TC as a first-line regimen in a test-and-treat setting, including among participants with very high baseline VL.

Disclosures. **Charlotte-Paige M. Rolle, MD MPH**, Gilead Sciences (Grant/Research Support, Scientific Research Study Investigator, Speaker's Bureau)**Janssen Infectious Disease** (Scientific Research Study Investigator, Advisor or Review Panel member)**ViiV Healthcare** (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)**Tulika Singh, MD MS AAHIVS**, Gilead (Grant/Research Support, Advisor or Review Panel member)**ViiV** (Grant/Research Support, Advisor or Review Panel member, Speaker's Bureau) **Moti Ramgopal, MD FIDSA**, Abbvie (Scientific Research Study Investigator, Speaker's Bureau)**Gilead** (Consultant, Scientific Research Study Investigator, Speaker's Bureau)**Janssen** (Consultant, Scientific Research Study Investigator, Research Grant or Support, Speaker's Bureau)**Merck** (Consultant, Scientific Research Study Investigator)**ViiV** (Consultant, Scientific Research Study Investigator, Speaker's Bureau) **Dushyantha Jayaweera, MD, mrcog(uk), face**, Gilead (Research Grant or Support)**Janssen** (Research Grant or Support)**viiv** (Research Grant or Support) **Peter Leone, MD**, viiv healthcare (Employee) **Jessica Matthews, BS**, ViiV Healthcare (Employee) **Michael Cupo, Ph.D.**, GlaxoSmithKline (Employee) **Mark Underwood, PhD**, GlaxoSmithKline (Shareholder)**ViiV Healthcare** (Employee) **Kostas Angelis, PhD**, GSK (Employee, Shareholder) **Brian Wynne, MD**, ViiV Healthcare (Employee, Shareholder, I have shares in GSK, the part owner of ViiV) **Deanna Merrill, PharmD, MBA, AAHIVP**, GlaxoSmithKline (Shareholder)**ViiV Healthcare** (Employee) **Christopher T. Nguyen, MD**, ViiV Healthcare (Employee) **Jean A. van Wyk, MB,ChB**, GlaxoSmithKline (Shareholder)**ViiV Healthcare** (Employee) **Andrew Zolopa, MD**, GlaxoSmithKline (Shareholder)**ViiV Healthcare** (Employee)

76. Effects of the "Undetectable = Untransmittable" ("U=U") Educational Campaign on Treatment Outcomes and Perceptions among People Living with HIV in North American Countries

Frank Spinelli, MD[1]; Bruce Richman, JD[2]; Patricia De Los Rios, MSc[1]; Benjamin Young, MD, PhD[1]; Marvelous Muchenje, BSW, MSc. in Global Health[1]; Nicolas Van de Velde, PhD[1]; Chinyere Okoli, PharmD, MSc, DIP[1]; [1]ViiV Healthcare, Sag Harbor, NY; [2]Prevention Access Campaign, New York, New York

Session: O-16. HIV Treatment

Background. The educational campaign "Undetectable = Untransmittable" (U=U) began in 2016 to improve the well-being of people living with HIV (PLHIV) and recalibrate HIV-related social norms. As medical practice can vary by region, we examined reports from PLHIV in North American countries to identify if the campaign affected healthcare provider (HCP) communication of U=U and if positive health outcomes differed by U=U-informed status or country.

Methods. Data were collected from the 2019 Positive Perspectives survey of PLHIV in Canada (n=120), Mexico (n=63), and the United States (US; n=400) and stratified by country. Outcomes were self-rated mental and sexual health ("Good"/"Very good"), viral suppression, and sharing of HIV status. Treatment perceptions were also assessed.